Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Oslo Bors  >  Nattopharma ASA    NATTO   NO0010289200

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Nattopharma : How "Old" Are You Really? Find Out at NattoPharma's Booth at SSW 2017

share with twitter share with LinkedIn share with facebook
share via e-mail
09/13/2017 | 08:41am CEST

Newly Recognized Tool From iHeart Determines "Internal Age" Via Aortic Stiffness

OSLO, NORWAY and METUCHEN, NJ (September 13, 2017) - NattoPharma, the world leaders in Vitamin K2 research and development, has confirmed and cultivated an understanding that K2 supports cardiovascular health by activating proteins that inhibit arterial calcification. So it is understandable that NattoPharma is excited to be teaming with a company that has pioneered a system that helps to determine one's "internal age" by measuring aortic stiffness via pulse wave velocity (PWV). The iHeart system is the perfect complement to NattoPharma's clinically validated cardiovascular and bone support ingredient, MenaQ7® Vitamin K2 as MK-7.

The iHeart system calculates one's Internal Age, a measure of Aortic Stiffness relative to others the same age, using Aortic Pulse Wave Velocity (AoPWV). AoPWV is the speed a pulse wave travels down the aorta, the body's largest blood vessel. AoPWV has been proven to be a powerful predictor for risk of heart disease, stroke and dementia, while Aortic Stiffness has been linked to inadequate dietary intakes, specifically Vitamin K2, as substantiated in population and clinical studies. iHeart proves a snapshot of current heart health and objectively shows benefit of Vitamin K2 supplementation.

"By analyzing the fingertip arterial pulse signal, our system calculates the aortic pulse wave velocity within 30 seconds, which then allows users to track the effects of lifestyle choices on their internal age," says Dr. Jess Goodman, the creator of the iHeart system. 

A Canadian general practitioner and medical advisor at three long-term care facilities, Dr. Goodman is well aware of the importance of physical activity for health maintenance, he "wanted to provide a simple, easy-to-use metric that showed health benefit of regular exercise. Aortic stiffness served this purpose well, being a parameter proven to predict the risk of death from all causes and shown to improve with exercise."

"Our 3-year cardiovascular study measured pulse wave velocity to determine that a nutritional dose of MenaQ7 improved arterial stiffness. And now the iHeart system provides a quick, non-invasive way to calculate one's aortic pulse wave velocity, designating whether they could benefit from Vitamin K2 supplementation," says Eric Anderson, SVP Global Marketing and Business Development.

iHeart will be at NattoPharma's SupplySide West booth (P115) demonstrating this amazing technology, which is a perfect match for NattoPharma's clinically proven and patented MenaQ7® Vitamin K2 as MK-7.  

Plan to come by to get your iHeart measurement. Visit www.goiheart.com to find out more about the iHeart system, and www.MenaQ7.com to learn more about this expert Vitamin K2 brand.  

# # #

About NattoPharma

NattoPharma ASA, based in Norway, is the world's leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, and has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for

applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPahrma USA, Inc., in Metuchen, NJ. For more information, visit nattopharma.com.

About iHeart

VitalSines was founded by Dr. Jess Goodman to give people the ability to see health benefits from exercise, good diet, and stress management through health technology. Dr. Goodman has developed the iHeart System, a revolutionary method of analyzing the arterial pulse signal, objectively showing internal health changes related to Aortic Stiffness. The company is dedicated to providing people with devices and resources to optimize their health and wellness. 

For more information, please contact:

Kate Quackenbush, Director of Communications

NattoPharma USA, Inc.

Phone: 609-643-0749

E-mail: [email protected]



(c) 2017 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NATTOPHARMA ASA
05/09UPDATED RELEASE : Additional attachments to Invitation to AGM 2018
05/09NATTOPHARMA ASA : Invitation to Annual General Meeting 2018
05/09NATTO : Board member of nattopharma asa exercise options
05/09NATTOPHARMA : market update
04/13NATTOPHARMA ASA : Annual Report 2017
03/05NATTO : Mandatory notification of trade and disclosure of large shareholding
02/08NATTO : Options granted
02/08NATTO : Enhanced management structure aligned with focused business unit strateg..
02/08NATTO :  second half and preliminary full year 2017 earnings release
02/05NATTOPHARMA ASA : annual earnings release
More news
Duration : Period :
Nattopharma ASA Technical Analysis Chart | NATTO | NO0010289200 | 4-Traders
Kjetil Ramsøy Chief Executive Officer & Chief Financial Officer
Frode Marc Bohan Executive Chairman
Peter Stahl Chief Operations Officer
Hogne Vik Chief Medical Officer
Katarzyna Zdzislaw Maresz Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-11.45%325 801
PFIZER-0.91%208 713
NOVARTIS-8.30%194 397
ROCHE HOLDING LTD.-9.17%189 708